title: The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells.
abstract: Immunotherapy is a promising treatment for liver cancer. Here, we tested the ability of the attenuated hepatocellular carcinoma-specific Listeria vaccine (Lmdd-MPFG) to treat hepatocellular carcinoma (HCC) in a mouse model. Immunization with the vaccine caused a strong anti-tumor response, especially in mice reinfused with dendritic cells (DCs). In mice that were also administered DCs, tumor suppression was accompanied by the strongest cytotoxic T lymphocyte response of all treatment groups and by induced differentiation of CD4+ T cells, especially Th17 cells. Additionally, the Lmdd-MPFG vaccine caused maturation of DCs in vitro. We demonstrated the synergistic effect of TLR4 and NLRP3 or NOD1 signaling pathways in LM-induced DC activation. These results suggest that the Lmdd-MPFG vaccine is a feasible strategy for preventing HCC.
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wan
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Ci
authors.initials: C
authors.lastname: Cheng
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Zhe
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Runqiu
authors.initials: R
authors.lastname: Jiang
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Yan
authors.affiliation: Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Junwei
authors.initials: J
authors.lastname: Tang
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Yao
authors.affiliation: Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Beicheng
authors.initials: B
authors.lastname: Sun
authors.affiliation: Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000502:physiology; D002454:Cell Differentiation; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D004354:Drug Screening Assays, Antitumor; D015789:HLA-A2 Antigen / Q000235:genetics / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active; D008089:Listeria monocytogenes / Q000276:immunology*; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D009363:Neoplasm Proteins / Q000502:physiology; D053474:Nod1 Signaling Adaptor Protein / Q000502:physiology; D053473:Nod2 Signaling Adaptor Protein / Q000502:physiology; D051192:Receptors, Pattern Recognition / Q000502:physiology; D013154:Spleen / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000502:physiology; D014613:Vaccines, Attenuated / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D002352:Carrier Proteins; D016207:Cytokines; D015789:HLA-A2 Antigen; C573135:Lmdd-MPFG vaccine; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D009363:Neoplasm Proteins; C492716:Nlrp3 protein, mouse; D053474:Nod1 Signaling Adaptor Protein; C507873:Nod1 protein, mouse; D053473:Nod2 Signaling Adaptor Protein; C495945:Nod2 protein, mouse; D051192:Receptors, Pattern Recognition; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic
keywords: Lmdd-MPFG; PRRs; dendritic cells; hepatocellular carcinoma
references.citation: World J Gastroenterol. 2008 Jul 21;14(27):4300-8
references.pmid: 18666317
references.citation: J Immunol. 2013 Jan 1;190(1):334-9
references.pmid: 23225887
references.citation: Cell Immunol. 2011;268(2):79-86
references.pmid: 21457950
references.citation: Vaccine. 2012 Mar 30;30(16):2633-9
references.pmid: 22365841
references.citation: J Clin Invest. 2012 Mar;122(3):1082-96
references.pmid: 22307326
references.citation: Cell Mol Immunol. 2014 Mar;11(2):184-96
references.pmid: 24488178
references.citation: Cancer Res. 2009 Jul 15;69(14):5860-6
references.pmid: 19584282
references.citation: Dig Dis. 2009;27(2):175-88
references.pmid: 19546557
references.citation: Front Immunol. 2013 Dec 27;4:486
references.pmid: 24409181
references.citation: Oncogene. 2012 Apr 26;31(17):2140-52
references.pmid: 21927025
references.citation: Semin Oncol. 2012 Jun;39(3):311-22
references.pmid: 22595054
references.citation: J Immunol. 2010 Nov 15;185(10):5879-87
references.pmid: 20956351
references.citation: J Dermatol Sci. 2014 Mar;73(3):209-15
references.pmid: 24315204
references.citation: Cancer Res. 2004 Dec 15;64(24):8821-5
references.pmid: 15604239
references.citation: Biomed Res Int. 2014;2014:203693
references.pmid: 25089265
references.citation: Infect Immun. 2003 Apr;71(4):1748-54
references.pmid: 12654788
references.citation: Eur J Immunol. 2013 Aug;43(8):2126-37
references.pmid: 23619996
references.citation: Immunotherapy. 2011 Apr;3(4 Suppl):32-4
references.pmid: 21524167
references.citation: J Virol. 2000 Nov;74(21):9987-93
references.pmid: 11024127
references.citation: Immunity. 2005 May;22(5):561-70
references.pmid: 15894274
references.citation: J Hepatol. 1999 Aug;31(2):323-31
references.pmid: 10453947
references.citation: Bioeng Bugs. 2010 Jul-Aug;1(4):235-43
references.pmid: 21327055
references.citation: Oncoimmunology. 2012 Sep 1;1(6):822-828
references.pmid: 23162749
references.citation: J Clin Invest. 2008 Dec;118(12):3990-4001
references.pmid: 19033668
references.citation: Oncoimmunology. 2013 Aug 1;2(8):e25375
references.pmid: 24167764
references.citation: Oncology. 2007;72 Suppl 1:30-44
references.pmid: 18087180
references.citation: Cancer Immunol Immunother. 2011 Jul;60(7):931-42
references.pmid: 21431419
references.citation: Expert Rev Vaccines. 2013 May;12(5):493-504
references.pmid: 23659298
references.citation: Nat Immunol. 2012 Jan 08;13(2):162-9
references.pmid: 22231517
references.citation: Vaccine. 2011 Jan 10;29(3):476-86
references.pmid: 21070847
references.citation: J Hepatol. 2011 Apr;54(4):830-4
references.pmid: 21145836
references.citation: J Virol. 2006 Sep;80(18):8880-90
references.pmid: 16940500
references.citation: Vaccine. 2007 Oct 16;25(42):7470-9
references.pmid: 17854955
references.citation: Cancer Immunol Immunother. 2012 Dec;61(12):2227-38
references.pmid: 22644735
references.citation: Front Cell Infect Microbiol. 2014 May 12;4:51
references.pmid: 24860789
references.citation: Int Immunol. 2009 Apr;21(4):317-37
references.pmid: 19246554
references.citation: J Hepatol. 2011 Jun;54(6):1273-85
references.pmid: 21236312
references.citation: J Leukoc Biol. 2010 Dec;88(6):1207-16
references.pmid: 20884650
references.citation: Cancer Res. 2010 Dec 15;70(24):10161-9
references.pmid: 21159638
references.citation: FEMS Immunol Med Microbiol. 2007 Nov;51(2):350-62
references.pmid: 17760876
references.citation: Immunity. 2006 Oct;25(4):619-30
references.pmid: 17027298
references.citation: Expert Rev Vaccines. 2013 Oct;12(10):1139-54
references.pmid: 24124876
references.citation: Curr Gene Ther. 2010 Feb;10(1):46-55
references.pmid: 20158470
references.citation: Clin Cancer Res. 2012 Feb 1;18(3):858-68
references.pmid: 22147941
references.citation: Eur J Immunol. 2013 Oct;43(10):2543-53
references.pmid: 23784881
references.citation: Liver Int. 2008 Feb;28(2):175-88
references.pmid: 18251977
references.citation: Nat Rev Immunol. 2006 Jan;6(1):9-20
references.pmid: 16493424
references.citation: Trends Immunol. 2005 Aug;26(8):447-54
references.pmid: 15967716
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):749-51
references.pmid: 19188142
references.citation: Curr Opin Immunol. 2010 Feb;22(1):34-40
references.pmid: 20149616
references.citation: Hum Vaccin. 2011 May;7(5):497-505
references.pmid: 21422819
references.citation: Cancer Immunol Res. 2014 Sep;2(9):911-22
references.pmid: 24872025
references.citation: Dig Liver Dis. 2006 Apr;38(4):221-5
references.pmid: 16461021
references.citation: Int J Cancer. 2012 Oct 15;131(8):1733-43
references.pmid: 22610886
references.citation: Nat Med. 2010 Jan;16(1):90-7
references.pmid: 19966812
references.citation: Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12294-9
references.pmid: 25136133
references.citation: Gastroenterology. 2004 Nov;127(5 Suppl 1):S232-41
references.pmid: 15508089
references.citation: Front Microbiol. 2011 Jan 14;1:149
references.pmid: 21607087
references.citation: Hum Immunol. 2010 Mar;71(3):255-62
references.pmid: 20036295
references.citation: J Korean Med Sci. 2013 Oct;28(10):1415-23
references.pmid: 24133343
references.citation: Stem Cells. 2005 Feb;23(2):264-78
references.pmid: 15671149